| PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives M El Fakiri, NM Geis, N Ayada, M Eder, AC Eder Cancers 13 (16), 3967, 2021 | 42 | 2021 |
| A simple method for the synthesis of N-difluoromethylated pyridines and 4-pyridones/quinolones by using BrCF 2 COOEt as the difluoromethylation reagent A Gandioso, M El Fakiri, A Rovira, V Marchán RSC advances 10 (50), 29829-29834, 2020 | 10 | 2020 |
| Development and preclinical evaluation of [211At] PSAt-3-Ga: an inhibitor for targeted α-Therapy of prostate Cancer M El Fakiri, N Ayada, M Müller, L Hvass, TH Gamzov, AS Clausen, ... Journal of Nuclear Medicine 65 (4), 593-599, 2024 | 7 | 2024 |
| Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide M El Fakiri, AR Regupathy, L Uhlmann, N Ayada, NM Geis, LC Domogalla, ... Theranostics 14 (12), 4701, 2024 | 3 | 2024 |
| Preclinical characterization of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic application A Eder, AR Regupathy, M El Fakiri, L Domogalla, N Steinacker, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51, S321-S321, 2024 | | 2024 |
| Preclinical evaluation of [68Ga] Ga-BCY18469, a first-in-class EphA2-targeting radiotheranostic Bicyclic Peptide M El Fakiri, G Mudd, P Huxley, K McDonell, A Regupathy, LC Domogalla, ... Nuclear Medicine and Biology 126, 108628, 2023 | | 2023 |
| A new series of PSMA-targeting inhibitors for astatine-211 targeted radionuclide therapy of prostate cancer M El Fakiri, N Ayada, C Poulie, M Müller, T Gamzov, H Jensen, ... Journal of Nuclear Medicine 63 (supplement 2), 2878-2878, 2022 | | 2022 |
| Astatine-211 based PSMA-inhibitors for targeted alpha-therapy of prostate cancer C Poulie, M El Fakiri, N Ayada, T Gamzov, M Muller, H Jensen, ... Nuclear Medicine and Biology 108, S60-S60, 2022 | | 2022 |